Protocols for Prostate Cancer
| HIC 0510000719 Wm. Kevin Kelly M.D. A Randomized Double-Blind Placebo Controlled Phase III Study of Early vs. Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone (CALGB 90202) |
| HIC 0707002902 Wm. Kevin Kelly M.D. A Phase II Trial Evaluating te Safety and Feasibility of Comibination Tretament Using Androgen-Deprivation Therapy (ADT) and Bevacizumab in Patients with Recurrent Androgen-dependent Prostate Cancer |
| HIC 0703002444 John Colberg CALGB 90203: A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Suppression Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High Risk, Clinically Localized Prostate Cancer |
| HIC 0703002453 Roy Decker M.D., PhD (RTOG 0521) A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer |
| HIC 0805003781 Kenneth Roberts Prostate Edema Associated with Interstitial Brachytherapy |
| HIC 0703002467 Wm. Kevin Kelly M.D. A Phase II Trial of Phenoxodiol in Patients with Castrate and Non-Castrate Prostate Cancer |
| HIC 0801003428 Wm. Kevin Kelly M.D. A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy |
| HIC 0904005035 Wm. Kevin Kelly M.D. A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer |
| HIC 0801003427 Wm. Kevin Kelly M.D. A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer |